All In Biotech

Drug Trial Radar · NCT06155487

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase 1 Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability After Oral Administration of AJH-2947 in Healthy Korean or Caucasian Male Subjects

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

Dec 5, 2023

Primary completion

Apr 28, 2026

Study completion Apr 28, 2026

Sponsor

Lead sponsor
JMackem Co., LtdIndustry
Sponsor type
Industry
Collaborators
Seoul National University Hospital
First posted
Dec 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this randomized, double-blind, placebo-controlled Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of AJH-2947 in healthy Korean or Caucasian adult male participants.

Conditions

  • Healthy Volunteers
  • Chronic Pain Syndrome

Interventions

  • AJH-2947 tablets or placeboDrug

    Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A (SAD): Maximum observed plasma concentration (Cmax)Time frame: Day 1 to Day 7
  2. Part A (SAD): Area under the concentration-time curve to the last quantifiable concentration (AUClast)Time frame: Day 1 to Day 7
  3. Part A (SAD): Area under the concentration-time curve extrapolated to infinity (AUCinf)Time frame: Day 1 to Day 7
  4. Part B (MAD): Maximum observed plasma concentration following the first dose (Cmax)Time frame: Day 1 to Day 2
  5. Part B (MAD): Area under the concentration-time curve over the dosing interval following the first dose (AUCtau)Time frame: Day 1 to Day 2
  6. Part B (MAD): Maximum observed plasma concentration at steady state (Cmax,ss)Time frame: Day 7 to Day 8
  7. Part B (MAD): Area under the concentration-time curve over the dosing interval at steady state (AUCtau,ss)Time frame: Day 7 to Day 8
  8. Number of participants with AEs, SAEs, and clinically significant safety findingsTime frame: From signing informed consent through the post-study visit (up to Day 18)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.